CRL Charles River Laboratories
Q1 2025 10-Q
Filed: May 7, 2025Period ending Mar 29, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Charles River Laboratories (CRL) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 7, 2025 for the fiscal period ending Mar 29, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ1 2025 10-Q
Risk Factors
- • New risk from U.S. tariffs on imports from Vietnam, Mauritius, and China impacting supply chain and operating margin as of early April 2025
- • Most updated risk: NIH policy reducing research grants for indirect overhead announced Feb 7, 2025, currently under preliminary injunction but with uncertain final outcome
Quarterly Financial SummaryXBRL
Revenue
$984M
▼ -2.7% YoY
Net Income
$25M
▼ -65.1% YoY
Net Margin
2.6%
▼ -462bp YoY
Source: XBRL data from Charles River Laboratories Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Charles River Laboratories Quarterly Reports
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.